Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03450161
Other study ID # AGO/2017/005
Secondary ID 2017-003278-15
Status Completed
Phase Phase 4
First received
Last updated
Start date May 14, 2018
Est. completion date January 9, 2021

Study information

Verified date December 2018
Source University Hospital, Ghent
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Randomized, double-blinded, three arm study in adult patients undergoing first time coronary artery bypass grafting (CABG) surgery with median sternotomy. The investigators will examine the effects of three fentanyl dosing schemes (high-dose bolus, low-dose bolus, continuous dose) on the area of hyperalgesia and allodynia at 24 and 48h as well as on persisting pain at 3, 6, and 12 months. Additionally, the investigators will measure fentanyl concentrations throughout anesthesia.


Description:

A prospective, randomized, double-blinded (patient, anesthesiologist, assessor) clinical study. This study will examine three different clinically used application schemes of fentanyl, an opioid used as the standard of care in routine practice. Patients will be randomized to receive one of the following three treatment arms for anesthesia maintenance (pre-sternotomy): 1. High-dose fentanyl bolus (20 µg/kg of body weight [BW]; e.g. 70kg 1400 µg or 1.4mg) 2. Low-dose fentanyl bolus (3 µg/kg BW; e.g. 70kg 210 µg or 0.2mg) 3. Continuous fentanyl application by Shibutani scheme This study will include data from 69 adult patients (23 per arm) undergoing first time, elective, on-pump CABG surgery with median sternotomy and central cannulation. Following randomization by the sealed envelope technique, fentanyl kits will be drawn up by an anesthesiologist not involved in patient care or outcome assessment. Patients with preexisting chronic pain, opioids in the last 30 days, a BMI>36kg/m2, sleep apnoea, renal failure (clearance <30ml/min), with neuraxial anesthesia, pregnant, with planned wound infiltration, known allergies/intolerance to opioids, and unable to understand pin-prick testing will be excluded. At induction, all patients will receive a standard 3 µg/kg bolus of fentanyl (not study medication, but rather standard of care). 5 minutes prior to sternotomy, the patient will receive analgesia maintenance (one of the three fentanyl study arms). Clinicians will at all times be able to administer a bolus of fentanyl on a perceived "as needed" basis (not study medication, but rather standard of care). The primary objective of this trial is to assess whether or not different intraoperative dosing schemes of fentanyl during on-pump CABG surgery influence the area of hyperalgesia as measured by sternal pin-prick testing on the first postoperative day. As the mechanisms causing opioid-induced analgesia are poorly understood but appear to be dosis-related, the investigators will examine 3 clinically used fentanyl application schemes in cardiac surgery: 1) a high-dose bolus group, 2) a low-dose bolus group, and 3) a low-dose continuous infusion group. [i.e. does fentanyl dosing influence the area of hyperalgesia?] The secondary objectives of this trial are 1) to explore the intraoperative concentrations of fentanyl in these various dosing schemes during and after extracorporeal circulation (ECC). [i.e. determine the time course of fentanyl with ECC and its association with hyperalgesia; explorative] 2) to explore a possible association between fentanyl dosing, hyperalgesia, and persisting pain 3, 6, and 12 months after surgery. [i.e. clinical implication on persistent/chronic pain; explorative]


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date January 9, 2021
Est. primary completion date February 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Consenting patients aged =18 years - Undergoing first-time, elective, on-pump CABG surgery with median sternotomy and central cannulation. Exclusion Criteria: - Documentation of preexisting chronic pain as per electronic record - Use of opioids in the last 30 days or history/documentation of opioid abuse as per electronic record - BMI > 35kg/m2 or history of obstructive sleep apnea syndrome - Patients with renal failure (clearance < 30 ml/min) - Neuraxial anesthesia - Pregnancy - Planned wound infiltration with local anesthetics - Known drug allergies or intolerance to fentanyl or other opioids - Expected to be unable to understand pinprick/allodynia testing / follow-up questions

Study Design


Intervention

Drug:
Fentanyl dosing schemes
We routinely use fentanyl as the opioid of choice in CABG surgery. However, how much and whether or not to apply it in boli or continuously remain uncertain. We will apply 3 routinely used fentanyl dosing schemes in our hospital. To blind care-givers and patients, in each of the arms a bolus and a continous injection will occur, as delineated in the treatment arms.

Locations

Country Name City State
Belgium University Hospital Ghent Ghent Oost-Vlaanderen

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Ghent University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Area of hyperalgesia at 24h Determination of secondary, wound hyperalgesia by pin prick (256mN von Frey filament) 24 hours after surgery (+/- 3 hours)
Secondary Area of hyperalgesia at 48h Determination of secondary, wound hyperalgesia by pin prick (256mN von Frey filament) 48 hours after surgery (+/- 3 hours)
Secondary Area of allodynia at 24h Determination of allodynia by cotton swab 24 hours after surgery (+/- 3 hours)
Secondary Area of allodynia at 48h Determination of allodynia by cotton swab 48 hours after surgery (+/- 3 hours)
Secondary Persistent Pain at 3 months Validated questionnaire to assess pain after by1) mail and 2) phone follow-up 3 months after surgery (+/- 1 week)
Secondary Persistent Pain at 6 months Validated questionnaire to assess pain after by1) mail and 2) phone follow-up 6 months after surgery (+/- 1 week)
Secondary Persistent Pain at 12 months Validated questionnaire to assess pain after by1) mail and 2) phone follow-up 12 months after surgery (+/- 1 week)
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run as specified by the time frame of this outcome and the following outcomes. 5 min. (+/- 1 min) prior to sternotomy, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 5 min. (+/- 1 min) after fentanyl/placebo bolus, given just prior to sternotomy
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 30 min. (+/- 1 min) after fentanyl/placebo bolus, given just prior to sternotomy
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run just prior (<1min) to start of pump run, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 5 min. (+/- 1 min) after begin of pump run, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 20 min. (+/- 1 min) after begin of pump run, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 40 min.(+/- 1 min) after begin of pump run, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 60 min.(+/- 1 min) after begin of pump run, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 80 min. (+/- 1 min) after begin of pump run, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 100 min. (+/- 1 min) after begin of pump run, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 120 min.(+/- 1 min) after begin of pump run, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 140 min.(+/- 1 min) after begin of pump run, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 160 min.(+/- 1 min) after begin of pump run, a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run 5 min.(+/- 1 min) after end of pump run,a surgical step
Secondary Description of perioperative fentanyl concentrations with on-pump extra corporeal circulation Fentanyl will be measured from samples taken prior to, during, and after a pump run end of surgery (+/- 5 min)
See also
  Status Clinical Trial Phase
Completed NCT05480111 - The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy Phase 4
Completed NCT06129305 - Erector Spina Muscle Distance From the Skin at Different Thoracal Elevations
Completed NCT04401826 - Micro-surgical Treatment of Gummy Smile N/A
Recruiting NCT04020133 - the Role of Popliteal Plexus Block in Pain Management After Anterior Cruciate Ligament Reconstruction. N/A
Completed NCT03023462 - Efficacy of an Anterior Quadratus Lumborum Block vs. a TAP-block for Inguinal Hernia Repair N/A
Completed NCT03546738 - Spinal Cord Burst Stimulation for Chronic Radicular Pain Following Lumbar Spine Surgery N/A
Completed NCT03652103 - Efficiency of Erector Spinae Plane Block For Patients Undergoing Percutaneous Nephrolithotomy Phase 4
Recruiting NCT03261193 - ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain Phase 3
Withdrawn NCT03528343 - Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy Phase 1/Phase 2
Completed NCT02525133 - Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty Phase 3
Completed NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Enrolling by invitation NCT05316168 - Post Operative Pain Management for ACL Reconstruction Phase 3
Recruiting NCT04130464 - Intraperitoneal Infusion of Analgesic for Postoperative Pain Management Phase 4
Enrolling by invitation NCT04574791 - Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty N/A
Completed NCT04073069 - Scalp Infiltration With Diprospan Plus Ropivacaine for Postoperative Pain After Craniotomy in Adults Phase 4
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Recruiting NCT05351229 - Intrathecal Morphine for Analgesia in Video-assisted Thoracic Surgery Phase 4
Enrolling by invitation NCT05543109 - Ultrasound Guided Psoas Compartment Block vs Suprainguinal Fascia Iliaca Compartment Block N/A
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04919317 - Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty Phase 2